文献速递肝病

核苷(酸)类似物停药对乙型肝炎病毒相关慢加急性肝衰竭患者生存结局的影响

Effect of Nucleos(t)ide Analogues Withdrawal on Survival Outcomes in Patients With Hepatitis B Virus-Related Acute-on-Chronic Liver Failure.
PubMed 文献 · Aliment Pharmacol Ther · 2025-05-29

这项多中心回顾性队列研究纳入中国四家三级医院的313例HBV-ACLF患者,其中66例(21.1%)经历核苷(酸)类似物停药。多因素Cox回归显示,停药与90天死亡率(HR 1.610;95%CI 1.095-2.365;p=0.015)和180天死亡率(HR 1.549;95%CI 1.057-2.271;p=0.025)显著相关,倾向性评分匹配和逆概率治疗加权后结果一致。

要点

  • 313例HBV-ACLF患者中66例(21.1%)发生核苷(酸)类似物停药。
  • 停药组90天死亡风险HR 1.610(95%CI 1.095-2.365;p=0.015)。
  • 停药组180天死亡风险HR 1.549(95%CI 1.057-2.271;p=0.025)。

核心结论

  • 核苷(酸)类似物停药是HBV-ACLF患者死亡的独立危险因素,强调慢性乙型肝炎患者坚持核苷(酸)类似物治疗的重要性。

研究设计与样本

  • 多中心回顾性队列研究,回顾性纳入中国四家三级医院连续收治的HBV-ACLF患者,共313例,其中66例(21.1%)经历核苷(酸)类似物停药。
  • 采用多因素Cox回归分析评估核苷(酸)类似物停药与全因死亡的关系,并进行倾向性评分匹配和逆概率治疗加权敏感性分析。

主要发现

  • 核苷(酸)类似物停药组较未停药组在诊断时肝酶水平更低、感染率更高。
  • 调整人口学和临床混杂因素后,核苷(酸)类似物停药与90天死亡率显著相关(HR 1.610;95%CI 1.095-2.365;p=0.015)。
  • 核苷(酸)类似物停药与180天死亡率显著相关(HR 1.549;95%CI 1.057-2.271;p=0.025)。
  • 倾向性评分匹配和逆概率治疗加权后,上述关联保持一致。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND/AIMS: Nucleos(t)ide analogues (NA) withdrawal is an important cause of hepatitis B virus (HBV) infection relapse or flare, potentially triggering HBV-related acute-on-chronic liver failure (HBV-ACLF). Although both NA withdrawal and spontaneous severe acute exacerbation (SAE) of chronic hepatitis B are recognised HBV-ACLF triggers, comparative evidence regarding their distinct clinical trajectories remains absent. This multicenter retrospective cohort study sought to determine whether NA withdrawal independently predicts adverse outcomes in HBV-related ACLF compared to SAE-induced cases. METHODS: We retrospectively enrolled consecutive patients with HBV-ACLF admitted to four tertiary hospitals in China. The relationship between NA withdrawal and all-cause mortality in HBV-ACLF patients was evaluated using multivariate Cox regression analysis. Additionally, sensitivity analyses including propensity score matching (PSM) and inverse probability treatment weighting (IPTW) were performed. RESULTS: Among the 313 HBV-ACLF patients, 66 patients (21.1%) experienced NA withdrawal. HBV-ACLF patients in the NA-withdrawal group exhibited lower liver enzyme levels and higher infection rates at diagnosis compared with those in the NA-naïve group. Multivariate Cox regression models indicated that, after adjusting for demographic and clinical confounders, NA withdrawal was significantly associated with 90-day mortality (hazard ratio [HR], 1.610; 95% confidence interval [CI], 1.095-2.365; p = 0.015) and 180-day mortality (HR, 1.549; 95% CI, 1.057-2.271; p = 0.025). Notably, the association remained consistent following PSM and IPTW. CONCLUSIONS: NA withdrawal is an independent risk factor for death in patients with HBV-ACLF, underlining the importance of adherence to NA therapy in patients with chronic hepatitis B.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Lin Y, Yu X, Lin H, et al. Effect of Nucleos(t)ide Analogues Withdrawal on Survival Outcomes in Patients With Hepatitis B Virus-Related Acute-on-Chronic Liver Failure. Aliment Pharmacol Ther. 2025. PMID: 40443167. doi:10.1111/apt.70213

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。